MAVORIXAFOR - Generic Drug Details

What are the generic sources for mavorixafor and what is the scope of patent protection?

Mavorixafor is the generic ingredient in one branded drug marketed by X4 Pharms and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mavorixafor has fifty-one patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for MAVORIXAFOR

International Patents:	51
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
Patent Applications:	992
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MAVORIXAFOR
What excipients (inactive ingredients) are in MAVORIXAFOR?	MAVORIXAFOR excipients list
DailyMed Link:	MAVORIXAFOR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MAVORIXAFOR

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MAVORIXAFOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
X4 Pharmaceuticals	PHASE1
X4 Pharmaceuticals	Phase 1
X4 Pharmaceuticals	Phase 3

See all MAVORIXAFOR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for MAVORIXAFOR

L03AX	Other immunostimulants
L03A	IMMUNOSTIMULANTS
L03	IMMUNOSTIMULANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for MAVORIXAFOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes			Y
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes			Y
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes			Y
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes

International Patents for MAVORIXAFOR

Country	Patent Number	Title	Estimated Expiration
Japan	2021181501	免疫不全疾患を処置するための方法 (METHODS FOR TREATING IMMUNODEFICIENCY DISEASES)
Japan	2021535146
Denmark	3393468
World Intellectual Property Organization (WIPO)	2017106332
Canada	3008272	METHODES DE TRAITEMENT DU CANCER (METHODS FOR TREATING CANCER)
Japan	6864296

Last updated: February 14, 2026

What Are the Market Dynamics for Mavorixafor?

Mavorixafor is an oral CXCR4 antagonist developed by X4 Pharmaceuticals for the treatment of rare hematologic indications, primarily Whisperer syndrome (adults with WHIM syndrome) and certain oncologic conditions involving the CXCR4 pathway. Its market potential relates primarily to orphan drug status, affecting competitive landscape, regulatory pathways, and commercial viability.

Key Drivers

• Orphan drug designation: Grants exclusivity and accelerates regulatory review, reducing competition. Mavorixafor received orphan status from the FDA and EMA for its primary indications.
• Unmet medical need: WHIM syndrome has no approved targeted therapies, positioning Mavorixafor as a leading candidate.
• Pipeline development: Its potential extends to other CXCR4-mediated conditions, including non-Hodgkin lymphomas and multiple myeloma, broadening its market scope.
• Clinical progression: Positive Phase 2 data demonstrating efficacy in increasing neutrophil counts, decreasing infections, and manageable safety profiles bolster commercial prospects.

Market Challenges

• Limited patient population: WHIM syndrome affects an estimated 100-2,000 worldwide, constraining sales volume.
• Competitive landscape: No approved targeted therapies exist for WHIM; however, supportive treatments like G-CSF are used off-label.
• Pricing and reimbursement: As an orphan drug, pricing strategies must balance high development costs with limited payer willingness.

Regulatory and Market Access

• Regulatory milestones: Fast-track designation accelerates approval; pivotal Phase 3 trials are underway.
• Market entry timing: Anticipated U.S. FDA approval in 2024 and potential EMA decision in 2024/2025.
• Pricing strategies: Orphan drugs typically command premium prices, possibly exceeding $200,000 annually per patient.

Market Size Estimates

Indicator	Estimate
Global prevalence of WHIM	100-2,000 patients
U.S. patient population	~50-80 patients (estimated)
Annual revenue potential (per patient)	$200,000+ (based on orphan pricing)

Potential Market Expansion

• Oncologic indications: CXCR4 antagonism may be effective in multiple myeloma and certain lymphomas; development is in early phases.
• Combination therapy niches: Potential for Mavorixafor to complement existing treatments, especially in resistant cancers.

What Is the Financial Trajectory for Mavorixafor?

Mavorixafor's financial outlook depends on development progress, regulatory approval, pricing, and adoption rates within its Isolated indications.

R&D Expenditure

• Development costs primarily include clinical trials (Phase 2/3), regulatory filings, and manufacturing scale-up.
• X4 Pharmaceuticals reported R&D expenses of approximately $44.1 million in 2022, with increased investments expected as trials progress.

Revenue Projections

• 2024: Anticipated launch post-approval, with initial revenues likely below $20 million due to limited patient access and early-stage commercialization.
• 2025-2027: Revenues could increase to $50-100 million if approval is granted and uptake occurs rapidly, assuming pricing around $200,000 per patient annually.
• Long-term outlook: Expansion into broader indications and possible off-label use could drive revenues well above $200 million per year, contingent on clinical successes and regulatory approvals.

Cost of Goods Sold (COGS) and Margins

• Orphan drugs typically feature lower COGS due to manufacturing efficiencies at small volume scales.
• Gross margins could reach 80% or higher post-approval, assuming efficient commercialization.

Investment and Partnering

• Potential partnerships with large pharmaceutical firms may offset marketing costs and accelerate market entry.
• X4 Pharmaceuticals may seek licensing deals in non-U.S. markets, providing upfront payments and milestone-based revenues.

Risks to Financial Trajectory

• Clinical failure could eliminate prospects.
• Regulatory delays or unfavorable pricing decisions.
• Competitive entrants or alternative therapies emerging.

How Do the Market and Financial Outlooks Compare?

Aspect	Market Dynamics	Financial Trajectory
Size and scope	Small, orphan population targeting niche indications	Limited initially, growth possible with broader indications
Regulatory outlook	Favorable with orphan designation, accelerated approvals	Dependent on successful regulatory milestones
Revenue potential	$200 million+ if broad adoption and premium pricing	Projected initial revenues <$20 million, scaling over years
Key risks	Limited patient pool, clinical and regulatory hurdles	Clinical trial outcomes, market access, payer reimbursement

Key Takeaways

• Mavorixafor's market hinges on its orphan drug status, targeting large unmet needs in WHIM syndrome.
• The drug's commercial prospects depend on successful regulatory approval expected in 2024.
• Revenue projections suggest a modest start with significant growth potential if expanded to other CXCR4-involved diseases.
• Financials are impacted by development costs, pricing strategies, and market adoption.
• Ongoing clinical results and regulatory decisions are critical factors influencing valuation and market success.

FAQs

1. What is the primary indication for Mavorixafor?
It is designed for WHIM syndrome, a rare immunodeficiency disorder caused by CXCR4 mutations.

2. When is regulatory approval expected?
FDA approval is anticipated in 2024; EMA approval follow in 2024 or 2025.

3. What is the market size for Mavorixafor?
Estimated at 100-2,000 patients worldwide, with about 50-80 in the U.S.

4. How much revenue could Mavorixafor generate annually?
Potentially over $200 million if widely adopted and priced at institutional orphan drug levels.

5. What are the main risks to commercial success?
Limited patient population, clinical trial risks, regulatory delays, and payer reimbursement challenges.

---

References

1. X4 Pharmaceuticals. Corporate Presentation. 2023
2. U.S. Food and Drug Administration. Drug Approval Records. 2023.
3. Orphan Drug Designations Database. FDA. 2023.
4. Market research reports on rare hematologic disorders. 2022.
5. Clinical trial registries and disclosures. 2023.